Mirati Therapeutics, Inc(NASDAQ:MRTX) 
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NS...
Website: http://www.mirati.com
Founded: 1995
Full Time Employees: 111
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2023-07-26
P
O 30.65
H 30.65
L 29.84
C 29.98
V 971,461
10EMA 29.98
20EMA 29.98
60EMA 29.98
120EMA 29.98
250EMA 29.98